Mojave Jane Brands (“Mojave Jane” or the “Company“) (CSE:JANE, OTC: HHPHF, FSE:OHCN), a California cannabis company, today announced that it has signed a binding letter of intent (“LOI”) to acquire 100% of CB Asset Management (“CBAM”), a fully-licensed cannabis operator based in Coachella with a 20-year lease on a six-acre property in the Coachella valley. The acquisition includes a licensed, operational Type 6 (ethanol) manufacturing facility that is expected to immediately boost Mojave Jane’s capacity and meet growing market demands for quality extracts.

The LOI also includes licenses for distribution and roughly 4 acres of cultivation, and represents a crucial step in the Company’s strategy to own its supply chain for raw material. Mojave Jane already shares a building with CBAM on the property which will accelerate the integration of both complementary businesses and ensure continuity of operations.


The acquisition will be completed through a combination of debt, equity and cash and via a “vend-in” through Greensource, LLC (“Greensource”).  Greensource holds the rights to acquire CBAM, and the LOI establishes that, at closing, Mojave Jane will own those rights and will conclude the acquisition of CBAM which will then be fully integrated with Mojave Jane. The closing is expected within 30 days of this announcement, and specific terms of the agreement will be released at closing.

Coincident with the addition of CBAM’s production capacity, Mojave Jane is in receipt of upgraded extraction and distillation equipment at its licensed and staffed Avenue 48 facility in Coachella. Together, CBAM and Mojave Jane are going to be able to produce roughly 170 litres of distillate monthly, and deliver it to the market as both white label and branded products.

Mojave Jane’s CEO, Gary Latham commented:

“The demand for high quality, compliant extracts in California far outpaces supply.  The CBAM acquisition will immediately expand our production capacity, our sales reach, and our team to satisfy that demand and produce meaningful revenue starting now. The acquisition will also give us the property we need to cultivate at a scale that meets our own demands for manufactured products and provides a base of operations for distribution in this part of the state.  Having this “right-sized” cultivation site is a key part of our strategy to fully control our supply chain and develop and grow the specific strains that best meet our product requirements.”

Michael Kaplan, CBAM’s Managing Partner commented:

“The team at Mojave Jane understands how the cannabis business works in the Coachella Valley and more broadly, in California, and they share our desire to produce the highest quality products.  Becoming a part of this team will allow CBAM to realize our vision of a production-class facility that benefits our customers and the Valley.  We are proud to put our asset under their expert management and to work closely with their team to build a larger success story in California cannabis.”

About Mojave Jane Brands

Mojave Jane Brands Inc. is a Canadian-based cannabis sector brand and distribution company emerging as a true vertical integrator in California’s legal cannabis space serving recreational and wellness markets. The Company’s U.S. holdings are comprised of assets set up as a vertical stack including cultivation to scale, branding, packaging, manufacturing & processing, as well as, a distribution arm and the edibles brand CALIGOLD. Operating out of licensed strategic locations within the state, Mojave Jane is leveraging its consumer and brand-focused business model to generate sustainable profits delivering quality product by recognized brands.

Social Media
Facebook: facebook.com/mojavejane
Twitter: twitter.com/mojavejane
LinkedIn: linkedin.com/mojavejane
CALIGOLD Instagram: https://www.instagram.com/caligoldofficial

Stock Exchanges

Mojave Jane trades in Canada, ticker symbol JANE on the CSE, and in Europe, ticker symbol 0HCN on the FSE. Neither the CSE, nor the FSE has approved nor disapproved the contents of this press release. Neither the CSE, nor the FSE accepts responsibility for the adequacy or accuracy of this release.

Marijuana Industry Involvement

Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate. Marijuana is legal in certain states however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Mojave Jane’s ability to access private and public capital could be affected and or could not be available to support continuing operations.

On behalf of the Board of Directors

Mojave Jane Brands Inc.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the intention of the parties to complete the Acquisition and certain ancillary transactions contemplated thereby. These transactions are subject to a number of material risks, and there is no assurance that they will be completed on the terms or within the timeframes currently contemplated, or at all. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

All monetary references herein refer to Canadian dollars unless otherwise specified.

SOURCE Mojave Jane Brands Inc.

For further information: about Mojave Jane, please contact: 8 Wellington St. E. Mezzanine Level | Toronto, On | M5E 1C5 | www.MojaveJane.com; Gary Latham, Chief Executive Officer & Director, Email: info@mojavejane.com, Phone: (760) 552-7122

 

Click here to connect with Mojave Jane (CSE:JANE) for an Investor Presentation.

Source: www.newswire.ca

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less